TRPS1 and extramammary Paget disease: Therefore, these findings suggest that no single IHC marker can reliably distinguish prostatic secondary EMPD, underscoring the need for a comprehensive IHC panel including CK7, CK20, TRPS1, PSA, and NKX3.1 rather than reliance on a single immunostain (Figure 6).